Both political parties want to lower the price of drugs, but differ in how they think it should be done. Gail Wilensky, PhD, of Project HOPE, explained her opinion that spurring more competition would be a more successful approach than directly implementing price controls.
Both political parties want to lower the price of drugs, but differ in how they think it should be done. Gail Wilensky, PhD, of Project HOPE, explained her opinion that spurring more competition would be a more successful approach than directly implementing price controls.
Transcript (slightly modified)
Drug pricing is the one area that Republicans and Democrats seem to agree that something needs to be done. Do you believe there will be bipartisan legislation addressing drug costs? What might that look like?
It’s not obvious to me that the drug pricing, at the end of the day, will be any easier. Democrats usually mean at the end of the day they want to control directly price increases or pricing on drugs; most Republicans don’t. Even though it sometimes sounds like the White House might, the Republican congress isn’t likely to do so.
It may be possible to get legislation that has more transparency about drug pricing, that also provides more support for expedited review by the FDA, but we may need to wait to see how much the 21st Century Cures Act, which also attempts to do that, works and if there are other areas that are needed.
So, they are both interested in the issue of putting downward pricing on drugs. I like the strategies that make competition more likely to occur and therefore expedited review or other ways to try to up the competition. I’m one of the limited number of people who actually had an opportunity to see what it’s like to implement price controls in healthcare, running Medicare and Medicaid. I’m not impressed that we would do ourselves a favor if we introduce that into the drug pricing world.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More